|
|
||||
|
Published by : PROFESSIONAL MEDICAL PUBLICATIONS |
||||
|
ISSN 1681-715X |
||||
|
||||
|
- |
||||
|
ORIGINAL ARTICLE |
||||
|
- |
||||
|
Volume 24 |
October - December 2008 (Part-II) |
Number 6 |
||
|
|
||||
|
|
||||
Immunogenicity and Economic Evaluation of Different
Recombinant Hepatitis–B Vaccines in Different
Dosages, Schedules, and routes of Administration
Babar Mumtaz1, Masood Siddiq2
ABSTRACT
Objective: To measure the immunogenic response produced by recombinant DNA derived vaccines in different dosages, schedules, and routes of administration. Another objective was to evaluate the minimum dosage and compliant schedule of recombinant DNA derived vaccine required to produce effective immune response and its economic evaluation in the adult population.
Methodology: Five hundred fifty eight healthcare workers in the age group of 20-50 years from Military Hospital Rawalpindi, Pakistan and other sister institutions were enrolled. Two hundred fifty eight were excluded due to serological evidence of HBV infection. Remaining three hundred were divided into five groups each having sixty volunteers with equal male to female ratio and age groups 20-29,30-39, 40-50. First four groups were injected with Heberbiovac vaccine and last group-V was given inj. Engerix–B. In Heberbiovac arm: Group-I received standard dose of 20µg at standard schedule of zero, one and six months intramuscularly. In Group-II, dose was reduced to half (10µg) intramuscularly. Group-III was given only two standard doses of 20µg at zero and one month interval intramuscularly and Group-IV received intradermal dose of 3µg at zero, one & six months. Group-V was given Engerix –B in standard dosage & schedule, (i.e., 20µg at zero, one and 6 months). Immunogenic response was measured in all the groups eight weeks after the last dose. Response was measured with MEIA/IMX system by ABBOTT.
Results: Both the vaccines were equally immunogenic but higher titers of Anti HBs was achieved with Heberbiovac. In Heberbiovac arm of study, seroprotection rate was 96.36% in Group-I, in Group-II it was 94.64%, in Group-III 95% and in intradermal group 98.14%. In Engerix –B group it was 92%.
Conclusion: Two doses/Half dose schedule/intradermal route of 3µg of Inj. Heberbiovac is equipotent to that of standard dose/schedule of Inj. Heberbiovac or Inj. Engerix–B in terms of seroprotection rate achieved.
KEYWORDS: Recombinant hepatitis–B vaccine, Immunogenicity.
Pak J Med Sci October - December 2008 (Part-II) Vol. 24 No. 6 833-837
How to cite this article:
Mumtaz B, Siddiq M. Immunogenicity and Economic Evaluation of Different Recombinant Hepatitis–B Vaccines in Different Dosages, Schedules, and routes of Administration. Pak J Med Sci 2008;24(6):833-37.
1. Babar Mumtaz, FCPS
Naval Central Surgery,
9-Brunton Road,
Behind Marriot Hotel,
Karachi – Pakistan.
2. Prof. Masood Siddiq, FCPS
Foundation University Medical College,
Jhelum Road,
Rawalpindi - Pakistan.
Correspondence
Dr. Babar Mumtaz, FCPS
Naval Central Surgery, 9-Brunton Road,
Behind Marriot Hotel, Karachi – Pakistan.
E-mail: babar_doctor@yahoo.com
* Received for Publication: August 20, 2008
* 1st Revision Received: October 27, 2008
* 2nd Revision Received: November 3, 2008
* Final Revision Accepted: November 13, 2008
HOME | SEARCH | CURRENT ISSUE | PAST ISSUES
Professional
Medical Publications
Room No. 522, 5th Floor, Panorama Centre
Building No. 2, P.O. Box 8766, Saddar, Karachi - Pakistan.
Phones : 5688791, 5689285 Fax : 5689860
pjms@pjms.com.pk
